There are currently several GLP-1 receptor agonists used clinically for the treatment of both type 2 diabetes mellitus and obesity, for example, liraglutide, lixsenatide, semaglutide, dulaglutide and exenatide [13]. This evidence concerns the gene GLP1R and diabetes mellitus.